Tyme Technologies, Inc. (TYME)
| Market Cap | 136.04M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.80M |
| Shares Out | 188.95M |
| EPS (ttm) | -0.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,231,085 |
| Open | 0.790 |
| Previous Close | 0.790 |
| Day's Range | 0.700 - 0.800 |
| 52-Week Range | 0.660 - 4.990 |
| Beta | 0.87 |
| Analysts | Buy |
| Price Target | 9.50 (+1,219.4%) |
| Earnings Date | Nov 8, 2021 |
About TYME
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for t...
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for TYME stock is "Buy." The 12-month stock price forecast is 9.50, which is an increase of 1,219.44% from the latest price.
News
TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Res...
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financ...
TYME Technologies, Inc. to Present at Jefferies London Healthcare Conference
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced ...
TYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ET
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...
TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patien...
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (“TYME” or the “Company”) (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...
TYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry Conferences
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...
TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced fi...
TYME Technologies, Inc. to Host Conference Call and Webcast on Tuesday, August 10th at 8:30 AM ET
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...
Tyme Technologies Stock Rallies: A Technical Analysis
Shares of Tyme Technologies, Inc. (NASDAQ: TYME) may have just crashed into a wall of sellers. This means the rally may be over.
TYME Stock: The Cancer Treatment News That's Boosting Tyme Today
TYME stock is making big moves today after it received patent approval for its cancer treatment. Now, it will move into deeper development.
Tyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer
BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that it has received notific...
Best Biotech Penny Stocks to Buy? 3 to Watch Before Monday
Looking for biotech penny stocks to watch before Monday? Check these 3 out The post Best Biotech Penny Stocks to Buy?
Tyme Stock Is Trading Higher On Pipeline Update After Strategic Review, Q4 Earnings
Tyme Technologies Inc (NASDAQ: TYME) announced a breast cancer trial with Georgetown University named OASIS. Enrollment is expected to start in Q3 of 2021.
Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Repo...
BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (Nasdaq:TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today reporte...
3 Biotech Penny Stocks That Are Popular on Reddit Right Now
Looking for biotech penny stocks on Reddit? Check these 3 out for your watchlist The post 3 Biotech Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News a...
Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List
Biotech penny stocks are pushing up; here's 4 for your watchlist The post Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List appeared first on Penny Stocks to Buy, Picks, News and In...
Best Penny Stocks in 2021 So Far? Here's 4 You Should Check Out
These penny stocks are pushing up, should you add them to your watchlist? The post Best Penny Stocks in 2021 So Far?
TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTstm), today annou...
3 Penny Stocks To Watch Under $2 Making Big Moves Today
Looking for top penny stocks to buy under $2? Check these 3 out for some watchlist inspiration The post 3 Penny Stocks To Watch Under $2 Making Big Moves Today appeared first on Penny Stocks to Buy, Pic...
2 Meme Stocks Test Resistance For A Larger Move
Express Inc (NYSE:EXPR) and Tyme Technologies Inc (NASDAQ:TYME) skyrocketed in January and February after gaining the attention of the WallStreetBets community. Now known as meme stocks, along with Game...
TYME Appoints Frank L. Porfido as Chief Financial Officer
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “Tyme”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...
TYME Announces Abstract Selected for Publication at the 2021 American Society of Clinical Oncology Annual Meeting
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “Tyme”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...
TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer
BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of Jan...
Why Tyme Technologies Stock Is Taking Off Today
The company closed a $100 million public stock offering.
TYME Announces Closing of $100 Million Registered Direct Offering of Common Stock
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that today it clos...
Why Tyme Stock Got Demolished Today
The clinical-stage biotech provides investors with a quarterly update.